Author Archives: Jonathan Montagu

About Jonathan Montagu

CEO of HotSpot Therapeutics

ESMO Reflections: Glimmers of Hope with the Next Wave of I-O Therapies?
October 10, 2024

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC HotSpot’s trip to Barcelona for the recent European Society of Medical Oncology (ESMO) Annual Meeting was no ‘European Vacation,’ but it was certainly

Leave a comment

Has Spring Sprouted New Growth in Immuno-Oncology?
May 9, 2024

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC As Boston’s weather has started its turn from the frigid darkness that is a northeast winter to the longer days and lighter conditions

Leave a comment

Signaling Complexes: A Ripe Opportunity for Drug Development
January 3, 2024

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Signaling pathways are the intricate networks that govern cell behavior, lying at the crux of cell function. They are used by nature to

Leave a comment

Build It & They Will Come: Momentum Building For CBL-B Inhibition
March 1, 2023

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more recent times has

Leave a comment

What Took So Long: How Tech Has Finally Caught Up With Transcription Factors
December 6, 2022

By Gerry Harriman and Jonathan Montagu, CSO and CEO, respectively, and co-founders of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. HotSpot Therapeutics today announced a strategic collaboration with Abbvie to develop IRF5 transcription factor inhibitors

Leave a comment

Hacking the Human Cell – How Once ‘Un-druggable’ Proteins Became the New Frontier in Drug Development
June 21, 2022

By Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system by

Leave a comment

Staying Human in the Age of Artificial Intelligence
March 9, 2022

By Jonathan Montagu, CEO of HotSpot Therapeutics, and Ramy Farid, CEO of Schrodinger, as part of the From The Trenches feature of LifeSciVC. No, your next doctor will not be a robot. Nor will an algorithm cure cancer. However, AI

Leave a comment

Hitting The Spot
November 29, 2021

By Jonathan Montagu, CEO and Co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Today marks an important point in our journey to patients as HotSpot Therapeutics announces its $100MM Series C financing.  This infusion

Leave a comment

Immuno-Oncology: The Comeback Kid
July 13, 2021

By Tim Reilly & Jonathan Montagu, CDO and CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4)

Leave a comment

Reimagining The Workplace Post Pandemic
April 15, 2021

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace.  CEO’s that I have spoken

Leave a comment

The Business Of Science
May 21, 2020

This blog was written by Jonathan Montagu, CEO and co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. Today marks an important milestone for HotSpot Therapeutics as we announce our Series B financing, but it

Leave a comment

Cats And The Future Of Machine Learning In Drug Discovery
April 9, 2019

This blog was written by Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. The predictions around the impact of artificial intelligence (AI) have been broad reaching but it’s clear that

Leave a comment

Float Like A Butterfly: Agility In Biotech
June 13, 2018

This blog was written by Jonathan Montagu, CEO and co-founder of Hotspot Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around

Leave a comment

Allostery: Realizing The Promise
March 5, 2018

This blog was written by Jonathan Montagu, CEO of Hotspot Therapeutics and Atlas EIR, as part of the From The Trenches feature of LifeSciVC. It starts off with flu-like symptoms and progresses to a perpetual low-grade fever, excessive sweating and

Leave a comment

Target Practice
August 18, 2014

Every life sciences company needs to make good program choices.  Big pharma creates value through smart portfolio management while small biotech companies can be defined by a single lead asset.  In both cases, the opportunity cost of poor decision-making can

Leave a comment

Biotech’s Virtual Reality
June 4, 2014

Much has been written about the merits and demerits of the virtual biotech model.  In essence, a virtual biotech outsources all non-core activities and rejects the need for in-house laboratories.  Instead, a small internal team manages execution outside the company,

3 Comments

Chemistry’s Age of Enlightenment
March 20, 2014

Despite many decades of success, small molecule drug discovery appears to be increasingly challenged.  The likelihood of approval of a small molecule at phase 1 is approximately half that of a biologic; pharma companies have shifted their pipelines dramatically towards

1 Comment